Meet Our Team

A former Aetna executive, Jim Clement is a key expert on the Coeus senior leadership team.

Most recently, Jim served as Executive Director, Value-Based Care and Supply Chain Strategy at Aetna Healthcare, where he focused largely on proving the value of pharmaceutical therapies. Jim was responsible for transforming the financing of the pharmacy benefit and leading Aetna’s enterprise relationships with pharmaceutical manufacturers. Jim was responsible for maintaining administrative oversight for pharmacy benefit strategy, actuarial services, client pricing, network administration, analytics, and vendor management (inclusive of Aetna Pharmacy’s outsourced services to CVS), in addition to innovative contracting models to help drive value-based care.

Jim also served as a board member for sPCMA, collaborated with the Bipartisan Policy Center on innovative and value-based market access approaches for gene therapies, and served as an advisor to the Network for Excellence in Health Innovation (NEHI) on the publication of “Value-Based Contracting for Oncology Drugs.”

Joshua Greenblatt is the Senior Vice President of Access Marketing with Coeus. He creates strategies to address reimbursement issues, ensure affordability, and maximize brand performance across all managed market segments. 

With more than 25 years in the healthcare industry, Josh has diverse experience in managed markets, including market research, strategy design, pharmaceutical marketing, above-brand marketing, disease management, training, public sector health programs, provider network development and management, and clinical trial management.

Before he joined Coeus, Josh managed the west coast office for MediMedia Managed Markets (now ICON) for 11 years. Prior to that, Josh held leadership roles at Health Strategies Group (now Eversana), Universal Care, PacificCare (UnitedHealthcare) and University of California School of Medicine. 

Matthew Coll, Vice President of Market Insights at COEUS, has 15+ years of experience leading healthcare policy research and nearly a decade of experience specializing in market access research. He has led and advised on a wide range of market research engagements focused on pricing, market access, and contracting strategy. Matthew has led engagements in both US and EU markets and across a wide range of therapeutic areas, including rare/orphan diseases; oncology; neurology; and high prevalence/competitive categories such as diabetes, asthma/COPD, and immunology. Prior to joining COEUS, Matthew worked at Trinity Life Sciences and Health Strategies Group (now Eversana), where he designed and executed market research engagements to help biotech and pharma clients optimize their market access strategies.

Kim Gwiazdzinski, Vice President of Outcomes & Value at COEUS, is an experienced healthcare strategist who drives innovative solutions for clients. Her progressive mindset supports building market access strategies and taking them from development to execution. Kim interprets and applies emerging healthcare trends to payer-, provider-, and patient-directed initiatives. Known for her work in value-based contracting, Kim transforms complex clinical concepts into agreements that are operational and meet the objectives of all involved. Kim is a registered pharmacist with 20 years of managed markets experience that encompasses health plans (Cigna), PBMs (Prime), and pharma (Merck, AstraZeneca, Novo Nordisk). She specializes in managed markets strategy, value-based contracting, commercial innovation, pricing and contracting, and affordability.

Matt Paul is Sr Vice President of Value & Access at COEUS. Serving in the specialty insurance space for nearly two decades, Matt has strong product knowledge in terms of networks, administrators, carriers, and different levels of reinsurance that affect various self-funded plans nationally. Over the past few years, the focus has been on the emergence of high-cost Rx and therapies that have consistently breached employers’ stop loss deductibles and carriers’ excess of loss layer. Most recently, Matt served as SVP of Sales (Accident & Health) at Skyward Specialty Insurance, a company that focuses on underwriting employer medical excess policies (stop loss) for groups that self-fund their health insurance. In this role, he worked closely with senior leadership to identify specific risk segments that focused on cost containment for the underlying insured. Matt also engaged with regional and national producers, educating them about products, services, and vendors that could positively lower their catastrophic claim exposure.

Iris Tam has over 25 years of experience in healthcare, including hospital pharmacy, managed care, and the biopharmaceutical industry, and is currently Senior Director & Head of Medical Affairs and HEOR at Coeus.

In previous roles at Achaogen, Otonomy, and Genentech, Iris led Medical Affairs strategies and tactics that support market access, product value, and patient quality of care, including accountabilities for medical communications, HEOR, AMCP dossiers, compendia submissions, guideline bodies engagement, and scientific payer communications. Since 2008, Iris has been active on the AMCP Format Executive Committee, which oversees the AMCP Format for Formulary Submissions, including serving as the Committee’s Chair.

Doug Brown is Senior Vice President of Value and Access at COEUS. He has 30 years of pharmacy management experience, the last 18 years working with Magellan Rx where his focus was on government markets, working to address strategies that help improve operational efficiency and stakeholder value in Medicaid. Before becoming Chief Strategy Officer, he served as Vice President of both Account Management and Value Based Solutions. Doug provided subject matter expertise on federal and state government legislation that impacted state Medicaid programs and offered policymakers a national view of evolving events in Medicaid. He frequently met with CMS, NGA, and MACPAC as well as legislative officials to help shape Medicaid policy to benefit state Medicaid programs and the beneficiaries they serve. To that end, Doug developed the foundation for an Outcomes-Based Contracting program in Medicaid with the intent of pivoting the drug pricing discussion away from unit cost and toward reducing the total cost of care.